Assignee
REMD BIOTHERAPEUTICS INC
US·11 granted patents·8 pending applications·3 citations·filing 2015–2022
Top patents by PatentIndex Score
19 records- 0185US11319372B2Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4)REMD BIOTHERAPEUTICS INC·Filed 2018·Granted May 3, 2022·3 cites·18 claims
- 0262US11446376B2Methods for treating heart failure using glucagon receptor antagonistic antibodiesREMD BIOTHERAPEUTICS INC·Filed 2020·Granted Sep 20, 2022·0 cites·11 claims
- 0362US10765737B2Methods for treating heart failure using glucagon receptor antagonistic antibodiesREMD BIOTHERAPEUTICS INC·Filed 2016·Granted Sep 8, 2020·0 cites·11 claims
- 0462US2025145680A1Novel interferon variants and bifunctional fusion molecules thereofREMD BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0561US2022112294A1Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic AntibodiesREMD BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0656US11447555B2Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodiesREMD BIOTHERAPEUTICS INC·Filed 2020·Granted Sep 20, 2022·0 cites·12 claims
- 0755US2023151104A1Chemokine receptor 4 (cxcr4) antagonist antibodiesREMD BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0854US2020339697A1Methods For Treating Obesity And Nonalcoholic Fatty Liver Disease Or Nonalcoholic Steatohepatitis Using Glucagon Receptor Antagonistic AntibodiesREMD BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 0953US10626179B2Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodiesREMD BIOTHERAPEUTICS INC·Filed 2015·Granted Apr 21, 2020·0 cites·3 claims
- 1051US10752693B2Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodiesREMD BIOTHERAPEUTICS INC·Filed 2016·Granted Aug 25, 2020·0 cites·8 claims
- 1150US11629184B2Calcitonin gene-related peptide (CGRP) antagonist antibodiesREMD BIOTHERAPEUTICS INC·Filed 2019·Granted Apr 18, 2023·0 cites·16 claims
- 1250US11319376B2Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancerREMD BIOTHERAPEUTICS INC·Filed 2017·Granted May 3, 2022·0 cites·13 claims
- 1348US11332531B2Immunotherapy using antibodies that bind programmed death ligand-1 (PD-L1)REMD BIOTHERAPEUTICS INC·Filed 2017·Granted May 17, 2022·0 cites·19 claims
- 1446US11248049B2Immunotherapy using antibodies that bind Programmed Death 1 (PD-1)REMD BIOTHERAPEUTICS INC·Filed 2017·Granted Feb 15, 2022·0 cites·19 claims
- 1546US11242398B2Anti-OX40 antibodies and methods of activating OX40REMD BIOTHERAPEUTICS INC·Filed 2018·Granted Feb 8, 2022·0 cites·16 claims
- 1645US2019002577A1Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic AntibodiesREMD BIOTHERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 1744US2017143673A1Methods For Treating Heart Failure Using Glucagon Receptor AntagonistsREMD BIOTHERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 1840US2021079087A1Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)REMD BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1940US2019062441A1Methods For Treating Rare Genetic Disorders Using Glucagon Receptor Antagonistic AntibodiesREMD BIOTHERAPEUTICS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when REMD BIOTHERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →